Trial intelligence / Profile preview

Organ preservation after chemoradiotherapy followed by consolidation chemotherapy in locally advanced rectal cancer

2017-003057-42Phase 2Active

Sponsor: University Hospital Tübingen
Start: Oct 2017
Modality: Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, open-label, single-arm trial of oxaliplatin, fluorouracil and folinic acid in rectal cancer, sponsored by University Hospital Tübingen. Primary endpoint: Clinical complete response rate. Started Oct 2017; status: active.

Drugs

oxaliplatinfluorouracilfolinic acid

Conditions

rectal cancer

Beyond the preview

Go deeper on 2017-003057-42.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2017-003057-42.